---
provider: claude_code
model: claude-fable-5[1m], claude-haiku-4-5-20251001
cached: false
start_time: '2026-09-05T18:24:17.240788'
end_time: '2026-09-05T18:29:25.159309'
duration_seconds: 307.92
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Dilated Cardiomyopathy 1V
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-fable-5[1m]
  - claude-haiku-4-5-20251001
  web_search_requests: 3
  num_turns: 24
  total_cost_usd: 2.6841960000000005
  session_id: b1d24a02-25f9-413c-8bd3-39e674fbe785
  stop_reason: end_turn
  permission_denials: 2
  denied_tools:
  - Bash
  - mcp__pubmed__get_article_metadata
  assistant_text_blocks: 7
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderBillingError
  status_code: 402
  remedy: the account is out of credits
  retryable: false
- provider: claude_code
  succeeded: true
citation_count: 11
reference_validation:
  total_references: 9
  verified: 9
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 9
  on_topic: 5
  validator_version: 0.2.1
term_validation:
  total_terms: 33
  verified: 30
  not_found: 0
  obsolete: 0
  unverifiable: 3
  confabulation_rate: 0.0
  labels_checked: 4
  labels_matching: 1
  labels_mismatched: 1
  mislabelled_terms:
  - term_id: MONDO:0013373
    reported_labels:
    - MONDO
    ontology_label: dilated cardiomyopathy 1V
  labels_variant: 2
  unresolvable_prefixes:
  - CCID
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 1V
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 1V** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I'll research Dilated Cardiomyopathy 1V (CMD1V). Let me first load the research tools and check the local reference caches already present in this worktree.

Now let me read the cached references to ground the report in exact source text.

Confirmed: DCM1V is the PSEN2 locus (MONDO:0013373, ClinGen **Limited**). Now let me pull the two key primary papers (Li 2006; Gianni 2010) and OMIM/population-frequency context.

Both key papers are already cached locally. Reading them now.

I now have the core evidence base. Let me verify OMIM/identifier details and the population-frequency status of PSEN2 Ser130Leu with a few web searches.

I have all the material needed. Let me quickly sanity-check the ontology CURIEs I'll suggest against the repo's local term caches.

All research is complete. Here is the full report.

---

# Research Report: Dilated Cardiomyopathy 1V (CMD1V)

**Prepared:** 2026-09-05 · **Category:** Mendelian (contested) · **Primary gene:** PSEN2 (presenilin-2)

---

## 1. Disease Information

**Overview.** Dilated Cardiomyopathy 1V (CMD1V/DCM1V) is a numbered OMIM locus for autosomal dominant familial dilated cardiomyopathy (DCM) attributed to heterozygous missense variation in **PSEN2**, the presenilin-2 gene far better known as a cause of early-onset familial Alzheimer disease (AD3, OMIM 606889). The locus was defined by a single 2006 candidate-gene screen of 315 DCM probands that found the PSEN2 variant **Ser130Leu (S130L)** segregating with DCM and heart failure in two families (Li et al., *Am J Hum Genet* 2006; **PMID:17186461**, DOI: 10.1086/509900). It is the companion locus to CMD1U (OMIM 613694, PSEN1 Asp333Gly), defined by the same screen.

**Critical framing — the gene–disease relationship is not established.** The ClinGen Dilated Cardiomyopathy Gene Curation Expert Panel classifies PSEN2–DCM1V as **Limited** (SOP v10; re-evaluated 2024-10-04, approved by the DCM Working Group 2025-05-30, report dated 2026-03-04; ClinGen curation CCID:005915, assertion CGGV:assertion_9e20579f-efc7-4ccd-8653-85c0aafe788f). The panel's summary states: *"Two missense variants have been reported in 4 probands in two studies (Li et al. PMID: 17186461, Gianni et al. PMID: 20194882)… both of the reported missense variants have subsequently been found at a frequency higher than would be expected for a monogenic, pathogenic effect in population reference data sets. No new human genetic evidence has emerged since the last curation… The overall genetic evidence points decreased over time."* Limited is one tier above PSEN1's **Disputed** at the sibling CMD1U locus. Every claim below should be read through that lens.

**Identifiers.**

| System | ID | Note |
|---|---|---|
| OMIM (phenotype) | **613697** | "CARDIOMYOPATHY, DILATED, 1V; CMD1V" |
| OMIM (gene) | 600759 | PSEN2; the S130L allele is 600759.0008 |
| MONDO | **MONDO:0013373** | "dilated cardiomyopathy 1V" (confirmed in ClinGen validity table) |
| HGNC | HGNC:9509 (repo convention: `hgnc:9509`) | PSEN2 |
| Orphanet | No CMD1V-specific code; subsumed under the familial isolated DCM umbrella (ORPHA:154) | |
| ICD-10 / ICD-11 | I42.0 / BC43.0 (dilated cardiomyopathy, not locus-specific) | |
| MeSH | D002311 (Cardiomyopathy, Dilated — umbrella) | |
| UMLS/GTR condition | C3150958 | NIH Genetic Testing Registry |

**Synonyms:** CMD1V; DCM1V; cardiomyopathy, dilated, 1V; PSEN2-related dilated cardiomyopathy.

**Data provenance:** All clinical information derives from aggregated disease-level resources (OMIM, ClinGen) and two family/cohort studies — not EHR or population-level patient data.

---

## 2. Etiology

**Putative causal factor.** Heterozygous PSEN2 missense variant **c.389C>T, p.Ser130Leu** (reported by OMIM as a "756C-T transition in exon 5"; Alzforum annotates it to exon 6 of isoform 1; rs63750197; GRCh38 chr1:226885570 C>T). Li et al. 2006: *"A novel PSEN1 missense mutation (Asp333Gly) was identified in one family, and a single PSEN2 missense mutation (Ser130Leu) was found in two other families. Both mutations segregated with DCM and heart failure"* (PMID:17186461). A second study identified PSEN2 **p.Arg62His (R62H)** in 2 of 20 sequenced idiopathic DCM patients (Gianni et al., *Circulation* 2010; **PMID:20194882**, DOI: 10.1161/CIRCULATIONAHA.109.879510).

**Why causality is contested (risk-factor reading).**
- **Population frequency:** S130L appears in gnomAD v2.1.1 at allele frequency ≈ **6.6×10⁻⁴** (187 alleles) — far above expectation for a fully penetrant dominant DCM allele — and ClinGen states both variants are *"found at a frequency higher than would be expected for a monogenic, pathogenic effect."* Alzforum's ACMG assessment of S130L (for AD) is **Benign** with a "may be a risk factor" caveat (BS1, BS2 met; in the Alzheimer's Disease Sequencing Project it appeared in 28 cases vs 26 controls).
- R62H was likewise detected in AD cohorts at AF ≈ 0.016 and *"none of PSEN1-92delC, E318G or PSEN2 R62H was segregated with AD affection status in identified AD families"* (PMID:20194882).

**Genetic risk factors:** carriage of PSEN2 S130L (two pedigrees) or R62H (two sporadic iDCM probands). No susceptibility loci, modifier genes, or protective variants are documented for this locus.

**Environmental risk/protective factors and G×E:** None established. A speculative gene–environment axis exists at the expression level: presenilin-2 mRNA is upregulated >2-fold by combined hypoxia and glucose deprivation in rat H9c2 cardiac cells (*"Glucose deprivation itself caused significant up-regulation of the presenilin-2 (to 160%) and with low oxygen increased presenilin-2 level to over 200% of the control"* — Mohuczy et al., *Regul Pept* 2002; **PMID:12468103**), and PS2 expression is increased in failing canine left ventricle and normalized by cardiac contractility modulation therapy (Gupta et al., *Clin Transl Sci* 2009; **PMID:20443895**). ClinGen cites exactly these two expression studies as the experimental support for the relationship.

---

## 3. Phenotypes

All phenotype data derive from the two Li 2006 pedigrees (small-n caveat applies to every frequency statement).

| Phenotype | Type | Onset | Severity/course | Frequency in carriers | Suggested HPO |
|---|---|---|---|---|---|
| Dilated cardiomyopathy | Clinical sign (imaging) | Adult (36–55 y) | Milder than CMD1U; progressive | Partial penetrance — not all carriers affected | **HP:0001644** Dilated cardiomyopathy |
| Left ventricular dilatation | Imaging sign | Adult | Progressive | In affected carriers | **HP:4000141** Left ventricular dilatation |
| Reduced LV ejection fraction | Imaging/functional | Adult | Variable | In affected carriers | **HP:0012664** Reduced left ventricular ejection fraction |
| Congestive heart failure | Clinical syndrome | Adult | *"milder disease, and a more favorable prognosis"* than PSEN1 disease | Subset of affected | **HP:0001635** Congestive heart failure |
| Exertional dyspnea, palpitations (generic DCM symptomatology) | Symptoms | Adult | Variable | Not itemized per-carrier | **HP:0002875**, **HP:0001962** |
| Unaffected carrier state | — | — | — | ≥1 mutation-positive relative with normal cardiovascular screening (OMIM) | **HP:0003829** (Typified by incomplete penetrance — current HP label) |

Key quotes: *"The PSEN2 mutation showed partial penetrance, milder disease, and a more favorable prognosis"* (PMID:17186461). Per OMIM 613697: onset of cardiovascular disease occurred between **48 and 55 years** in one family; in the second family three sibs were diagnosed with DCM between **36 and 45 years**; one mutation-positive family member had normal cardiovascular screening.

**Quality-of-life impact:** No CMD1V-specific QoL data exist. Generic DCM/heart-failure QoL burden (fatigue, exercise intolerance, hospitalization) applies to affected members.

**Laboratory abnormality (research-grade):** *"Calcium signaling was altered in cultured skin fibroblasts from PSEN1 and PSEN2 mutation carriers"* (PMID:17186461) — elevated resting intracellular Ca²⁺ in carrier fibroblasts (Alzforum functional annotation). Not a clinical diagnostic finding.

---

## 4. Genetic/Molecular Information

- **Gene:** PSEN2 (HGNC:9509; OMIM 600759; chromosome **1q42** per OMIM, 1q42.13), 448-aa polytopic membrane protein; catalytic-capable subunit of the γ-secretase complex; homolog of PSEN1.
- **Variants reported for CMD1V:**
  - **p.Ser130Leu** (c.389C>T; rs63750197; GRCh38 chr1:226885570 C>T; OMIM allele 600759.0008). Missense; germline; heterozygous. Segregated with DCM in 2 families with partial penetrance. Functional data: **no effect on APP processing** (no change in Aβ42 or Aβ42/40 in vitro) but **altered calcium signaling** in carrier fibroblasts; in-silico "possibly damaging/damaging," CADD >20; computer modeling suggests loss of a PKC phosphorylation site at S130 (Alzforum). Also reported in early- and late-onset AD, posterior cortical atrophy, Parkinson disease dementia — with healthy-control observations driving a Benign/risk-factor ACMG call for AD. gnomAD v2.1.1 AF 6.6×10⁻⁴.
  - **p.Arg62His** (Gianni 2010): *"PSEN2 R62H enhances PS2 degradation, reduces PS2 stability and compromises Notch function"* (PMID:20194882, citing prior work); located in a divergent N-terminal "hot spot"; AD-cohort AF 0.016; did not segregate with AD.
- **Mechanistic class:** Uncertain. Neither variant has an established loss- vs gain-of-function assignment in myocardium; the fibroblast phenotype suggests altered Ca²⁺ handling rather than γ-secretase catalytic failure.
- **ClinVar/ACMG status:** Conflicting interpretations historically; current expert synthesis (Alzforum, ADSP data) is Benign-with-risk-factor-caveat for AD; no ClinVar pathogenic consensus for cardiomyopathy. **A PSEN2 variant should not be reported as a molecular diagnosis of DCM** given the Limited classification.
- **Modifier genes, epigenetics, chromosomal abnormalities:** None documented for this locus.

---

## 5. Environmental Information

No environmental, lifestyle, or infectious factors are implicated in CMD1V specifically. The generic DCM phenocopy environment (alcohol, anthracyclines, myocarditis, peripartum state) is relevant only to differential diagnosis (§10). The hypoxia/low-glucose induction of PS2 expression (PMID:12468103) is an in-vitro observation, not an exposure claim.

---

## 6. Mechanism / Pathophysiology

**Status:** hypothetical throughout. No cardiomyocyte carrying S130L has ever been studied; the causal chain below is an *inference scaffold*, and the single in-vivo cardiac calcium phenotype (Psen2-null mouse) runs in the **opposite direction** to the disease claim.

**Proposed causal chain (calcium-handling hypothesis):**
1. Heterozygous PSEN2 missense variant (S130L) **leads to** altered presenilin-2 protein function *(inferred; demonstrated only as altered Ca²⁺ signaling in carrier skin fibroblasts — PMID:17186461)*.
2. Presenilin-2 normally localizes to cardiomyocyte Z-lines and **physically interacts with the ryanodine receptor RyR2 and its modulator sorcin** — *"PS2, sorcin, and RyR2 interact with each other… PS2 colocalizes with RyR2 and sorcin at the Z-lines"* (Takeda et al., *FASEB J* 2005; **PMID:16204356**) — so variant PS2 **is proposed to result in** dysregulated sarcoplasmic-reticulum Ca²⁺ release and excitation–contraction coupling *(inferred; shown only for wild-type/knockout PS2, not for S130L)*.
3. Chronic cardiomyocyte Ca²⁺ dyshomeostasis **leads to** impaired contractile performance *(inferred from general heart-failure biology)*.
4. Sustained contractile impairment **results in** left ventricular remodeling and dilatation, reduced ejection fraction, and clinically manifest heart failure *(the observed family phenotype)*.

**Branch — proteostasis/oligomer hypothesis (Gianni 2010):** presenilin variants **lead to** altered protein quality control; misfolded-protein oligomers accumulate in iDCM myocardium (pre-amyloid oligomer staining in 5/6 iDCM hearts; tangle- and plaque-like fibrillar deposits by EM even in early-stage biopsies); applied oligomers **cause** *"a sudden increase in peak systolic Ca2+ transient together with an enhanced velocity of Ca2+ release"* in mouse cardiomyocytes, converging on the same Ca²⁺-dyshomeostasis step (PMID:20194882). This branch is generic to iDCM, not specific to PSEN2 carriers. The related PS1–SERCA2a co-immunoprecipitation belongs primarily to the sibling CMD1U story.

**Directly contradicting evidence:** Psen2-knockout mice show **increased** contractility and Ca²⁺ transients with *"no evidence of cardiac hypertrophy and fibrosis"* (PMID:16204356) — i.e., loss of PS2 alone does not produce DCM in mouse, and pushes calcium physiology the "wrong" way for a simple haploinsufficiency model.

**Ontology suggestions (verified against repo term caches unless flagged):** GO:0006874 intracellular calcium ion homeostasis; GO:0010880 regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; GO:0010882 regulation of cardiac muscle contraction by calcium ion signaling; GO:0016529 sarcoplasmic reticulum; GO:0007219 Notch signaling pathway (for R62H); GO:0006457 protein folding (oligomer branch); GO:0030018 Z disc *(unverified — validate before binding)*. Cell type: CL:0000746 cardiac muscle cell; CL:0000057 fibroblast (carrier assay tissue).

**Omics:** No CMD1V-specific transcriptomic/proteomic/single-cell datasets exist. Expression-level support only: PMID:12468103 (rat H9c2 macroarray + qRT-PCR), PMID:20443895 (failing dog LV: S100A1/sorcin/HRC decreased, **PS2 increased**, CCM therapy normalized S100A1/sorcin/PS2).

---

## 7. Anatomical Structures Affected

- **Organ:** heart (UBERON:0000948); primary chamber: heart left ventricle (UBERON:0002084); tissue: myocardium (UBERON:0002349; left ventricle myocardium UBERON:0006566). Secondary involvement: systemic congestion of heart failure. System: cardiovascular.
- **Cells:** cardiac muscle cell (CL:0000746). Research assays additionally used dermal fibroblasts (CL:0000057) from carriers.
- **Subcellular:** sarcoplasmic reticulum (GO:0016529) and its membrane (GO:0033017); Z-line/Z disc region (PS2–RyR2–sorcin colocalization); endoplasmic reticulum (presenilin residence).
- **Lateralization:** Not applicable (global LV disease).

---

## 8. Temporal Development

- **Onset:** adult, insidious. Family 1: cardiovascular disease onset 48–55 y; family 2: DCM diagnosed in three sibs at 36–45 y (OMIM 613697).
- **Progression:** chronic and progressive in affected members, but explicitly *"milder disease, and a more favorable prognosis"* than PSEN1-associated CMD1U, which required transplantation or ended in death (PMID:17186461).
- **Course pattern:** presumed progressive; no remission described; lifelong once manifest.
- **Critical periods:** none defined; family surveillance from early adulthood is the practical window (see §13).

---

## 9. Inheritance and Population

- **Inheritance:** autosomal dominant (ClinGen MOI: AD) with **partial penetrance** (HP:0000006; HP:0003829). No anticipation, germline mosaicism, founder effect, or consanguinity documented.
- **Epidemiology:** No prevalence or incidence exists and none can be estimated. The entire case literature is **2 missense variants in 4 probands** (ClinGen count): 2/315 probands in Li 2006 (0.6%; the paper's companion phrasing: presenilin mutations in *"0.9% of tested DCM families (3/325)"* counts the PSEN1 family too), plus 2/20 iDCM patients with R62H in Gianni 2010. These are variant-detection yields in selected cohorts, not disease prevalences.
- **Demographics:** Both founding families from a US familial-DCM cohort (Hershberger group, Oregon). Gianni's 4 presenilin-variant iDCM patients were all Caucasian women, prompting an untested estrogen/sex-modifier speculation (PMID:20194882). Population carrier frequency of S130L ≈ 0.066% (gnomAD v2.1.1) — itself the strongest argument against high-penetrance causality.

---

## 10. Diagnostics

- **Clinical work-up (standard DCM, not locus-specific):** echocardiography (LV dilatation + reduced LVEF), ECG, natriuretic peptides (BNP/NT-proBNP; LOINC-codable), cardiac MRI with late gadolinium enhancement, exclusion of ischemic/valvular/toxic causes.
- **Genetic testing:** In the founding era, targeted PSEN1/PSEN2 sequencing. Today, PSEN2 is **not a recommended DCM panel gene**: ClinGen's Limited classification means a PSEN2 variant in a DCM patient is weak evidence and *should not be returned as a molecular diagnosis*. WES/WGS will incidentally cover PSEN2; interpretation must apply the population-frequency evidence above (expect Benign/VUS-risk-factor calls for S130L). GTR lists tests under condition C3150958.
- **Differential diagnosis:** all other genetic DCM loci (TTN, LMNA, MYH7, TNNT2, DSP, FLNC, BAG3, RBM20, SCN5A, PLN, TAB2 …), plus phenocopies (ischemic, alcoholic, chemotherapy-induced, myocarditic, peripartum, tachycardia-induced) and infiltrative disease — notably cardiac amyloidosis, which is mechanistically adjacent to the oligomer hypothesis but is a distinct diagnosis (light-chain, transthyretin, desmin-related; PMID:20194882 background).
- **Screening:** cascade clinical screening (echo/ECG) of first-degree relatives per familial-DCM guidelines; predictive genetic testing for PSEN2 alone is **not** supportable at Limited validity.

---

## 11. Outcome/Prognosis

- No survival curves or registry data exist for CMD1V. The only comparative statement: PSEN2 disease showed *"partial penetrance, milder disease, and a more favorable prognosis"*, versus PSEN1-CMD1U's complete penetrance and *"progressive disease that resulted in the necessity of cardiac transplantation or in death"* (PMID:17186461).
- Complications, once DCM is established, are those of DCM generally: congestive heart failure (HP:0001635), arrhythmia, thromboembolism, sudden cardiac death (HP:0001645) — none specifically quantified in the two pedigrees.
- Prognostic factors/biomarkers: none locus-specific; standard heart-failure prognostics (LVEF, NYHA class, NT-proBNP) apply.

---

## 12. Treatment

There is **no PSEN2-specific therapy**; management is standard guideline-directed care for DCM/heart failure with reduced EF.

| Intervention | Notes | Suggested NCIT |
|---|---|---|
| Guideline-directed medical therapy (ACEi/ARB/ARNI, beta-blockers, MRA, SGLT2 inhibitors, diuretics) | Standard HFrEF pharmacotherapy | NCIT:C15986 Pharmacotherapy (+ CHEBI/NCIT `therapeutic_agent` per drug) |
| ICD / CRT device therapy | Standard indications; no locus-specific arrhythmia signal reported | Device pattern per repo convention (action term + device qualifier) |
| Heart transplantation | End-stage disease; notably *not* the reported course in the PSEN2 families (unlike CMD1U) | NCIT:C15289 Organ Transplantation |
| Cardiac contractility modulation (CCM) | Investigational HF electrotherapy; mechanistic contact point only — CCM normalized PS2/S100A1/sorcin expression in failing dog LV (PMID:20443895) | — |
| Genetic counseling | Required framing: Limited validity; variant carriage ≠ diagnosis | NCIT:C15240 Genetic Counseling |

Pharmacogenomics, gene/cell/RNA therapy, targeted therapy: none exist or are in trials for this locus (no CMD1V-specific NCT records).

---

## 13. Prevention

- **Primary prevention:** none possible (no proven modifiable cause).
- **Secondary prevention:** periodic clinical surveillance (echo/ECG) of first-degree relatives in the two known families and in any family where a segregating PSEN2 variant is suspected — driven by the familial-DCM phenotype, not by the genotype.
- **Genetic counseling:** must communicate (a) autosomal dominant transmission *within the reported pedigrees*, (b) partial penetrance, (c) the Limited ClinGen classification, and (d) that the cardiac classification is independent of PSEN2's established Alzheimer-disease role — an S130L result does not carry an AD diagnosis either (ACMG Benign/risk-factor for AD).
- Tertiary prevention: standard heart-failure disease management.

---

## 14. Other Species / Natural Disease

No naturally occurring PSEN2-mutant cardiomyopathy is known in any non-human species (no OMIA phenotype). Comparative data are all engineered or disease-context expression studies: dog (failing LV PS2 upregulation, *Canis lupus familiaris*, NCBITaxon:9615; PMID:20443895), mouse (NCBITaxon:10090), rat cell line (NCBITaxon:10116; PMID:12468103). Psen2 is evolutionarily conserved; mouse Psen2 is the ortholog used in all knockout work. No zoonotic/transmission relevance.

---

## 15. Model Organisms

| Model | Key finding | Recapitulation of CMD1V |
|---|---|---|
| **Psen2-knockout mouse** (Takeda 2005, PMID:16204356) | Viable; *"cardiac contractility in PS2KO mice increased"*; higher Ca²⁺ transients and peak tension; PS2–sorcin–RyR2 interaction; Z-line colocalization | **Fails to recapitulate** — opposite contractile direction, no dilatation, no fibrosis. This is the central model-fidelity problem for the locus (`FAILS_TO_RECAPITULATE`, with the caveat that a knockout is not an S130L knock-in) |
| **Psen1/Psen2 double-knockout mouse** | Un-looped heart at E8.5–9.0; presenilins essential for cardiac morphogenesis (PSEN1 single KO: VSD, DORV, PA stenosis) | Developmental-essentiality context only; not a DCM model |
| **Carrier dermal fibroblasts** (human, in vitro; PMID:17186461) | Altered calcium signaling; elevated resting [Ca²⁺] | Supports the Ca²⁺ hypothesis one tissue removed from myocardium |
| **Rat H9c2 cardiac cells** (PMID:12468103) | PS2 induced by hypoxia + glucose deprivation | Expression-level support only |
| **Failing-heart dog** (PMID:20443895) | PS2 increased in HF LV; normalized by CCM | Expression-level support only; not a genetic model |
| **Isolated mouse cardiomyocytes + Aβ oligomers** (PMID:20194882) | Oligomers acutely raise systolic Ca²⁺ transient | Tests the proteostasis branch, not PSEN2 variants |

**Missing model:** no S130L (or R62H) knock-in animal, iPSC-derived cardiomyocyte line, or engineered-tissue model exists — precisely the experiment that would move this locus off Limited.

---

## Summary Assessment for KB Curation

CMD1V is a **queried, historically established OMIM locus resting on a weak and shrinking evidence base**: two variants, four probands, two studies (2006, 2010), zero new human genetic evidence since, population frequencies incompatible with high-penetrance causality, and a knockout mouse pointing the wrong way. Curate the locus (it exists, is indexed, and is asked about), anchor it to MONDO:0013373, carry the ClinGen Limited assertion as first-class evidence, hold the calcium-handling mechanism inside an explicitly hypothetical grouping rather than as asserted pathophysiology, and state plainly that a PSEN2 variant is not a reportable molecular diagnosis of DCM.

**Primary citations:** PMID:17186461 (Li 2006, founding study); PMID:20194882 (Gianni 2010, second human study + oligomer mechanism); PMID:16204356 (Takeda 2005, Psen2-KO mouse / RyR2–sorcin); PMID:12468103 (Mohuczy 2002, cardiac PS2 expression); PMID:20443895 (Gupta 2009, failing-dog PS2 expression); CGGV:assertion_9e20579f-efc7-4ccd-8653-85c0aafe788f-2026-03-04T170000.000Z (ClinGen Limited, 2026).

Sources:
- [OMIM #613697 — Cardiomyopathy, Dilated, 1V; CMD1V](https://www.omim.org/entry/613697)
- [OMIM *600759 — Presenilin 2; PSEN2](https://omim.org/entry/600759)
- [ClinGen Gene-Validity report: PSEN2 / dilated cardiomyopathy 1V (Limited)](https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_9e20579f-efc7-4ccd-8653-85c0aafe788f-2026-03-04T170000.000Z)
- [Alzforum mutation page: PSEN2 S130L](https://www.alzforum.org/mutations/psen2-s130l)
- [Li et al. 2006, Am J Hum Genet — Mutations of presenilin genes in dilated cardiomyopathy and heart failure (PMID:17186461)](https://doi.org/10.1086/509900)
- [Gianni et al. 2010, Circulation — Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy (PMID:20194882)](https://doi.org/10.1161/CIRCULATIONAHA.109.879510)
- [Presenilin 1 is essential for cardiac morphogenesis (PubMed 15254914)](https://pubmed.ncbi.nlm.nih.gov/15254914/)
- [Conditionally targeted deletion of PSEN1 leads to diastolic heart dysfunction (J Cell Physiol)](https://onlinelibrary.wiley.com/doi/10.1002/jcp.26057)
- [NIH Genetic Testing Registry — Dilated cardiomyopathy 1V (C3150958)](https://www.ncbi.nlm.nih.gov/gtr/conditions/C3150958/)
- [MalaCards — Cardiomyopathy, Dilated, 1v](https://www.malacards.org/card/cardiomyopathy_dilated_1v)
- [Ensembl — rs63750197](https://jun2026.archive.ensembl.org/Homo_sapiens/Variation/Explore?v=rs63750197)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 9 |
| Resolved | 9 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 9 |
| On topic | 5 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 33 |
| Resolved | 30 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 3 |
| Terms whose name was checked | 4 |
| Terms named correctly | 1 |
| Terms named as a **different** term | 1 |
| Terms whose name is worth a second look | 2 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0013373` (3 mentions) - the report calls it "MONDO"; MONDO calls it **dilated cardiomyopathy 1V**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `GO:0016529` (2 mentions) - the report calls it "Subcellular:** sarcoplasmic reticulum"; GO calls it **sarcoplasmic reticulum**
- `UBERON:0000948` (1 mention) - the report calls it "Organ:** heart"; UBERON calls it **heart**, and lists "branchial heart" among its other names

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `CCID`, `ORPHA`.